Apixaban

Apixaban (manufacturer's designation BMS-562247-01) is a compound being investigated as an anticoagulant. It acts by inhibiting coagulation factor Xa. It is presently undergoing phase III trials in the prevention of venous thromboembolism, together with a number of related competing compounds, such as rivaroxaban.^[1] It is being marketed in a joint venture by Pfizer and Bristol-Myers-Squibb.^[2]

Additional recommended knowledge

How to ensure accurate weighing results every day?

Daily Sensitivity Test

Guide to balance cleaning: 8 simple steps

A 2007 trial showed that apixaban was equivalent to enoxaparin/open-label heparin in preventing thrombosis is patients who had undergone a knee replacement.^[3]

References

1. ^ Turpie AG (2007). "Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases". Arterioscler. Thromb. Vasc. Biol. 27 (6): 1238-47. doi:10.1161/ATVBAHA.107.139402. PMID 17379841.
2. ^ Bristol-Myers Squibb News Release 26 April 2007. Retrieved on 2007-09-15.
3. ^ Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D (2007). "The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement". J. Thromb. Haemost. 5 (12): 2368–75. doi:10.1111/j.1538-7836.2007.02764.x. PMID 17868430.